Table 1.
Clinical features before and after matching.
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Sorafenib (n = 56) | Non-sorafenib (n = 167) | P | Sorafenib (n = 42) | Non-sorafenib (n = 42) | P | |
| Sex, n (%) | 0.14 | 0.776 | ||||
| Male | 42 (75.0) | 140 (83.8) | 34 (81.0) | 35 (83.3) | ||
| Female | 14 (25.0) | 27 (16.2) | 8 (19.0) | 7 (16.7) | ||
| Age (years, median ± SD) | 54.4 ± 1.2 | 56.1 ± 0.9 | 0.238 | 54.2 ± 1.4 | 54.6 ± 1.7 | 0.573 |
| Age, n (%) | 0.399 | 0.826 | ||||
| >54 years | 32 (57.1) | 106 (63.5) | 24 (57.1) | 23 (54.8) | ||
| <54 years | 24 (42.9) | 61 (46.5) | 18 (42.9) | 19 (45.2) | ||
| Hepatitis, n (%) | 39 (69.6) | 148 (88.6) | 0.001 | 33 (78.6) | 34 (81.0) | 0.786 |
| Cirrhosis, n (%) | 47 (83.9) | 101 (60.5) | 0.001 | 34 (81.0) | 37 (88.1) | 0.365 |
| Tumor size (cm, median ± SD) | 6.5 ± 0.6 | 5.5 ± 0.3 | 0.206 | 6.2 ± 0.6 | 7.2 ± 0.8 | 0.573 |
| Tumor size, n (%) | 0.058 | 0.113 | ||||
| >5 cm | 32 (57.1) | 70 (41.9) | 23 (54.8) | 30 (71.4) | ||
| <5 cm | 24 (42.9) | 97 (58.1) | 19 (45.2) | 12 (28.6) | ||
| AFP, n (%) | 0.91 | >0.99 | ||||
| >20 ng/ml | 31 (55.4) | 91 (54.5) | 21 (50.0) | 21 (50.0) | ||
| <20 ng/ml | 25 (44.6) | 76 (45.5) | 21 (50.0) | 21 (50.0) | ||
| Number of tumors, n (%) | 0.83 | 0.459 | ||||
| Single | 41 (73.2) | 129 (77.3) | 13 (31.0) | 17 (40.5) | ||
| Multiple | 15 (26.8) | 38 (22.7) | 29 (69.0) | 25 (59.5) | ||
| PVTT, n (%) | 12 (21.4) | 12 (7.2) | 0.004 | 7 (16.7) | 9 (21.4) | 0.505 |
| Intrahepatic metastasis, n (%) | 25 (44.6) | 70 (41.9) | 0.721 | 17 (40.5) | 22 (52.4) | 0.274 |
| Tumor differentiation | 0.501 | >0.99 | ||||
| Low + moderate | 18 (32.1) | 62 (37.1) | 12 (28.6) | 12 (28.6) | ||
| High | 38 (67.9) | 105 (62.9) | 30 (71.4) | 30 (71.4) | ||
| TNM staging, n (%) | 0.005 | 0.525 | ||||
| I | 12 (21.4) | 73 (43.7) | 8 (19.1) | 5 (11.9) | ||
| II | 28 (50.0) | 69 (41.3) | 22 (52.4) | 21 (50.0) | ||
| III | 16 (28.5) | 25 (15.0) | 12 (28.6) | 16 (38.1) | ||
| Satellite lesions, n (%) | 24 (42.9) | 70 (41.9) | 0.902 | 18 (42.9) | 22 (52.4) | 0.382 |
| BCLC, n (%) (0/A/B/C) | 0.31 | 0.71 | ||||
| 0 | 5 (8.9) | 14 (8.4) | 5 (11.9) | 2 (4.8) | ||
| A | 20 (35.7) | 84 (50.3) | 16 (38.1) | 16 (38.1) | ||
| B | 19 (33.9) | 56 (33.5) | 14 (33.3) | 15 (35.7) | ||
| C | 12 (21.4) | 13 (7.8) | 7 (16.7) | 9 (21.4) | ||
| Recurrence, n (%) | 42 (75.0) | 124 (74.3) | 0.912 | 33 (78.6) | 37 (88.1) | 0.242 |
| Death, n (%) | 39 (69.6) | 122 (73.1) | 0.622 | 31 (73.8) | 35 (83.3) | 0.046 |
AFP, α-fetoprotein; PVTT, portal vein tumor thrombus; TNM, tumor-node-metastasis; BCLC, Barcelona Clinic Liver Cancer.